ROIV

Roivant Sciences Ltd

Add to Watchlist

Advanced Chart

14.875

-0.065(-0.435%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.990

Open

14.910

VWAP

14.94

Vol

978.32K

Mkt Cap

10.20B

Low

14.870

Amount

14.61M

EV/EBITDA(TTM)

Total Shares

738.72M

6.16B

EV/OCF(TTM)

P/S(TTM)

457.55

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

7.32M

-74.99%

-0.340

+9.84%

7.37M

-18.3%

-0.336

-246.01%

8.61M

+13.7%

-0.358

+23.42%

Estimates Revision

The market is revising Downward the revenue expectations for Roivant Sciences Ltd. (ROIV) for FY2026, with the revenue forecasts being adjusted by -27.75% over the past three months. During the same period, the stock price has changed by 29.39%.

Revenue Estimates for FY2026

Revise Downward

-27.75%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+6.83%

In Past 3 Month

Stock Price

Go Up

+29.39%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 20.31 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 14.875

Low

16.00

Averages

20.31

High

24.00

Current: 14.875

Low

16.00

Averages

20.31

High

24.00

H.C. Wainwright

Buy

maintain

$18 -> $20

2025-09-18

New

Reason

H.C. Wainwright

Price Target

$18 -> $20

2025-09-18

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Roivant Sciences to $20 from $18 and keeps a Buy rating on the shares. The firm is \"impressed\" by the Phase 3 VALOR data of brepocitinib in dermatomyositis. The \"fast and durable improvement across broad disease symptoms in brepo-treated patients is particularly significant,\" the analyst tells investors in a research note. H.C. Wainwright thinks brepocitinib is well positioned to become the first targeted therapy dermatomyositis in 2027.

JPMorgan

NULL -> Overweight

upgrade

$16 -> $20

2025-09-18

New

Reason

JPMorgan

Price Target

$16 -> $20

2025-09-18

New

upgrade

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Roivant Sciences to $20 from $16 and keeps an Overweight rating on the shares. The firm says the efficacy and safety from the VALOR study for brepocitinib in dermatomyositis \"were as clear as it could be.\" The efficacy was strong, as brepocitinib's effect on the TIS score fell within JPMorgan's win scenario, the analyst tells investors in a research note. The firm upped its probability of success to 90% for brepocitinib in the U.S. from 40%.

Guggenheim

analyst

NULL -> Buy

maintain

$15 -> $21

2025-09-18

New

Reason

Guggenheim

analyst

Price Target

$15 -> $21

2025-09-18

New

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Roivant Sciences to $21 from $15 and keeps a Buy rating on the shares after the company announced positive results from the Phase 3 VALOR Study of brepocitinib in treating dermatomyositis. ) Brepo 30 mg achieved a \"remarkable\" mean total improvement score of 46.5, notes the analyst, who updated the firm's model to include 100% odds of success of brepo in DM and estimates peak sales of about $2B based on about 50% peak penetration.

Jefferies

Buy

upgrade

$18 -> $20

2025-09-18

New

Reason

Jefferies

Price Target

$18 -> $20

2025-09-18

New

upgrade

Buy

Reason

Jefferies raised the firm's price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a Buy rating on the shares. After \"strong\" Phase 3 dermatomyositis data, the firm was hearing \"minimal pushback\" on DM in investor inbounds, but said \"rather nearly everyone has been asking about the LNP litigation.\" On the latter, the firm says it is focused on the Moderna (MRNA) case, where the jury trial won't be until March 2026, but the near term catalyst will be summary judgment and the judge's decision on '1498 that could come over the next two months before November 7.

TD Cowen

initiated

$24

2025-09-18

New

Reason

TD Cowen

Price Target

$24

2025-09-18

New

initiated

Reason

TD Cowen initiated a $24 price target for Roivant Sciences following the release of its announcement that its Brepo 30mg dose succeeded in Ph3 VALOR DM with robust and consistent statistical signifiant efficacy on all key endpoints.

BofA

Chi Fong

Neutral

maintain

$12

2025-09-18

New

Reason

BofA

Chi Fong

Price Target

$12

2025-09-18

New

maintain

Neutral

Reason

BofA analyst Chi Fong raised the firm's price target on Roivant Sciences to $16.50 from $12 and keeps a Neutral rating on the shares following positive Phase 3 results for brepocitinib in dermatomyositis. The data set the stage for brepo's commercial launch in 2027, says the analyst, who cites the positive data as well as recent progress in lipid nanoparticle litigation for the firm's higher target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Roivant Sciences Ltd (ROIV.O) is -10.69, compared to its 5-year average forward P/E of -7.16. For a more detailed relative valuation and DCF analysis to assess Roivant Sciences Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.16

Current PE

-10.69

Overvalued PE

-2.65

Undervalued PE

-11.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.08

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.66

Undervalued EV/EBITDA

-5.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

70.13

Current PS

0.00

Overvalued PS

134.36

Undervalued PS

5.90